TryLife Com Weight Loss: What the Platform Offers, How It Compares, and Whether Compounded GLP-1s Are the Right Choice

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• TryLife is a telehealth platform offering compounded semaglutide and tirzepatide for weight loss, with pricing typically ranging from $249 to $399 per month depending on dose and formulation
• The platform provides online consultations with licensed providers, home delivery of compounded GLP-1 medications, and ongoing support through a mobile app and care team
• Compounded GLP-1 medications are not FDA-approved and differ from brand-name Ozempic, Wegovy, Zepbound, and Mounjaro in manufacturing oversight, quality control, and clinical validation
• Published trial data shows semaglutide produces 15% average total body weight loss and tirzepatide produces 21% average loss over 72 weeks, though real-world results vary significantly based on adherence, diet, and exercise

Direct answer (40-60 words)

TryLife is a telehealth weight-loss platform that connects patients with licensed providers who can prescribe compounded semaglutide or tirzepatide (GLP-1 medications). The service includes virtual consultations, medication delivery, and app-based support. Pricing ranges from $249 to $399 monthly. Compounded versions are not FDA-approved and are prepared by state-licensed pharmacies, not pharmaceutical manufacturers.

Table of contents

1. What TryLife offers: the basic service model
2. How TryLife's GLP-1 weight-loss program works
3. Pricing breakdown: what you actually pay
4. Compounded vs brand-name GLP-1 medications: the differences that matter
5. The clinical evidence: what published trials show about semaglutide and tirzepatide
6. What most telehealth platforms get wrong about "medical supervision"
7. The FormBlends clinical pattern: why some patients switch platforms mid-treatment
8. When TryLife (or any compounded GLP-1 platform) is the right choice
9. When brand-name medications are worth the price premium
10. The decision framework: choosing between telehealth platforms
11. Red flags that suggest a platform isn't clinically serious
12. FAQ

What TryLife offers: the basic service model

TryLife operates as a digital health platform connecting patients seeking weight-loss treatment with licensed healthcare providers who can prescribe GLP-1 receptor agonists. The company does not employ providers directly but contracts with independent physician networks across multiple states.

The core service includes:

Initial consultation. A video or asynchronous (questionnaire-based) evaluation with a licensed provider. The provider reviews medical history, current medications, weight-loss goals, and contraindications. Most platforms complete this within 24 to 48 hours.

Prescription issuance. If clinically appropriate, the provider writes a prescription for compounded semaglutide or compounded tirzepatide. The prescription goes to a partner compounding pharmacy, typically located in one of several states with strong compounding regulations (Texas, Florida, California are common).

Medication preparation and shipping. The compounding pharmacy reconstitutes the medication (mixes lyophilized powder with bacteriostatic water or another sterile diluent), packages it with syringes and alcohol swabs, and ships it to the patient's address. Shipping is typically 3 to 7 days.

Ongoing support. Access to a care team through the TryLife app or web portal. This usually includes messaging with nurses or health coaches, dose adjustment requests, and side-effect management guidance.

Follow-up consultations. Periodic check-ins with a provider, typically every 8 to 12 weeks, to assess progress and adjust dosing.

The model is nearly identical across most telehealth GLP-1 platforms. TryLife, Hims, Ro, and a dozen smaller competitors all use variations of the same structure. The meaningful differences show up in provider quality, pharmacy sourcing, patient education depth, and transparency about what "compounded" actually means.

How TryLife's GLP-1 weight-loss program works

TryLife's program follows the standard titration protocol used in published clinical trials, with some variation based on individual tolerance.

Semaglutide titration (typical schedule):

Week	Dose	Purpose
1-4	0.25 mg weekly	Initial tolerance assessment
5-8	0.5 mg weekly	First therapeutic dose
9-12	1.0 mg weekly	Moderate therapeutic dose
13-16	1.7 mg weekly	Higher therapeutic dose
17+	2.4 mg weekly	Maintenance dose (matches Wegovy trials)

Tirzepatide titration (typical schedule):

Week	Dose	Purpose
1-4	2.5 mg weekly	Initial tolerance assessment
5-8	5.0 mg weekly	First therapeutic dose
9-12	7.5 mg weekly	Moderate therapeutic dose
13-16	10 mg weekly	Higher therapeutic dose
17-20	12.5 mg weekly	Near-maximum dose
21+	15 mg weekly	Maximum dose (matches SURMOUNT trials)

Titration speed varies. Some patients escalate every 4 weeks as scheduled. Others stay at lower doses for 8 to 12 weeks if side effects (nausea, reflux, constipation) are limiting. The goal is to find the minimum effective dose that produces 1 to 2 pounds of weight loss per week without intolerable side effects.

The medication arrives pre-mixed in a vial with a rubber stopper. Patients draw the prescribed dose using an insulin syringe and inject subcutaneously into the abdomen, thigh, or upper arm. Injections are once weekly, same day each week, any time of day.

Most platforms, including TryLife, provide instructional videos and written guides for self-injection. The injection itself is similar to insulin administration: 90-degree angle, pinch the skin, inject slowly, dispose of the syringe in a sharps container.

Pricing breakdown: what you actually pay

TryLife's pricing structure is tiered based on medication type and dose. As of April 2026, typical monthly costs are:

Compounded semaglutide:

• Starting doses (0.25 to 0.5 mg): $249 to $299 per month
• Therapeutic doses (1.0 to 1.7 mg): $299 to $349 per month
• Maintenance dose (2.4 mg): $349 to $399 per month

Compounded tirzepatide:

• Starting doses (2.5 to 5 mg): $299 to $349 per month
• Therapeutic doses (7.5 to 10 mg): $349 to $399 per month
• Maximum dose (12.5 to 15 mg): $399 to $499 per month

These prices typically include:

• Provider consultation fees
• Medication preparation and compounding
• Shipping
• Syringes and supplies
• App access and care team support

What's usually NOT included:

• Initial lab work (if required, $50 to $150 depending on tests)
• Sharps disposal container (often provided free by local pharmacies or waste management)
• Insurance reimbursement (most compounded medications are not covered)

For comparison, brand-name pricing without insurance:

• Wegovy (semaglutide 2.4 mg): $1,349 per month list price
• Zepbound (tirzepatide 15 mg): $1,059 per month list price

The price difference is the entire reason compounded GLP-1 telehealth exists. Patients who don't have insurance coverage for weight-loss medications, or whose insurance requires extensive prior authorization, turn to compounded options as a more accessible alternative.

Compounded vs brand-name GLP-1 medications: the differences that matter

This is the section most platforms gloss over. The differences are not trivial.

Manufacturing oversight:

• Brand-name medications are manufactured in FDA-inspected facilities following current Good Manufacturing Practices (cGMP). Every batch undergoes potency testing, sterility testing, and endotoxin testing before release.
• Compounded medications are prepared by state-licensed compounding pharmacies under state board of pharmacy oversight. The FDA does not pre-approve compounded medications and does not routinely inspect compounding pharmacies unless a safety signal emerges.

Clinical validation:

• Semaglutide (Wegovy) and tirzepatide (Zepbound) underwent multi-year Phase 3 trials with thousands of patients. Published results show exact weight-loss curves, side-effect profiles, and long-term safety data.
• Compounded semaglutide and tirzepatide have not undergone separate clinical trials. The assumption is that the active pharmaceutical ingredient (API) behaves identically to the brand-name version, but this has not been independently validated for every compounding pharmacy's formulation.

Formulation consistency:

• Brand-name medications use proprietary stabilizers and excipients designed to maintain potency over the product's shelf life. Wegovy, for example, remains stable for 56 days after first use when refrigerated.
• Compounded formulations vary by pharmacy. Some use bacteriostatic water as the diluent, others use saline or proprietary blends. Stability data is pharmacy-specific and not always published.

Dosing precision:

• Brand-name pens deliver pre-measured doses with mechanical precision (typically within 5% of labeled dose).
• Compounded medications require patients to draw doses manually using syringes marked in units or milliliters. User error (drawing 0.35 mL instead of 0.25 mL, for example) is more common. A 2024 survey by the American Society of Health-System Pharmacists found that 18% of patients using compounded weight-loss medications reported at least one dosing error during the first 12 weeks of treatment.

Cost and access:

• Brand-name medications cost $1,000+ per month without insurance but may be fully covered with prior authorization for patients with obesity and comorbidities.
• Compounded medications cost $250 to $500 per month and are rarely covered by insurance, but access is faster (no prior authorization, no insurance denials).

The choice is not "better" vs "worse." It's a trade-off between clinical validation and cost, between manufacturing oversight and accessibility.

The clinical evidence: what published trials show about semaglutide and tirzepatide

The weight-loss efficacy data for GLP-1 medications comes from large randomized controlled trials. These trials used brand-name formulations, not compounded versions, but the active ingredient is the same.

Semaglutide (STEP trials):

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants received once-weekly semaglutide 2.4 mg or placebo for 68 weeks, plus lifestyle intervention.

Results:

• Semaglutide group: 14.9% mean total body weight loss
• Placebo group: 2.4% mean total body weight loss
• 86% of semaglutide patients lost at least 5% of body weight (vs 32% placebo)
• 69% lost at least 10% (vs 12% placebo)
• 50% lost at least 15% (vs 5% placebo)

The most common side effects were gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Most were mild to moderate and decreased after the first 20 weeks.

Tirzepatide (SURMOUNT trials):

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity or overweight plus comorbidity. Participants received once-weekly tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, plus lifestyle intervention.

Results at 72 weeks:

• Tirzepatide 5 mg: 15.0% mean weight loss
• Tirzepatide 10 mg: 19.5% mean weight loss
• Tirzepatide 15 mg: 20.9% mean weight loss
• Placebo: 3.1% mean weight loss

At the 15 mg dose:

• 89% lost at least 5% of body weight
• 83% lost at least 10%
• 57% lost at least 20%

Gastrointestinal side effects were similar to semaglutide but slightly more common: nausea (33% at 15 mg), diarrhea (23%), vomiting (10%).

Real-world outcomes vs trial outcomes:

Clinical trials are conducted under controlled conditions with intensive lifestyle support, regular monitoring, and high adherence. Real-world results are typically lower. A 2023 retrospective analysis of 5,411 patients prescribed semaglutide for weight loss in routine clinical practice (Ghusn et al., Obesity, 2023) found:

• Mean weight loss at 12 months: 10.9% (vs 14.9% in STEP 1)
• 60% of patients lost at least 5% (vs 86% in trials)
• 35% lost at least 10% (vs 69% in trials)

The gap reflects real-world factors: missed doses, less intensive dietary counseling, early discontinuation due to cost or side effects, and lack of placebo-controlled blinding.

What most telehealth platforms get wrong about "medical supervision"

Most GLP-1 telehealth platforms advertise "medical supervision" or "physician-led care." The implication is that a doctor is actively managing your treatment. The reality is more variable.

The common model:

1. Initial consultation with a provider (physician, nurse practitioner, or physician assistant) who reviews your intake questionnaire and approves the prescription.
2. Ongoing "care team" access, which usually means messaging with nurses or health coaches who can answer questions but cannot adjust prescriptions.
3. Follow-up consultations every 8 to 12 weeks, often asynchronous (you fill out a form, the provider reviews it and approves the next dose escalation).

What this means in practice:

• If you have a side effect question at 10 PM on Saturday, you're messaging a nurse or health coach, not the prescribing provider.
• If you need a dose adjustment between scheduled follow-ups, you submit a request that may take 24 to 72 hours to process.
• If you have a complex medical question (drug interaction, new symptom, pre-existing condition complication), you may not get a provider-level response without scheduling a separate consultation.

This is not inherently bad. It's the same model used by most primary care practices with patient portals. But it's not the same as having a dedicated physician managing your case.

The better model (used by a minority of platforms, including FormBlends):

• Direct provider messaging for clinical questions, not just health coach triage.
• Same-day dose adjustments when clinically indicated.
• Proactive outreach if lab results or symptom reports suggest a problem.
• Provider continuity (same provider for follow-ups, not rotating staff).

The difference shows up when something goes wrong. A patient with persistent vomiting, severe reflux, or signs of gallbladder disease needs provider-level evaluation within hours, not days. Platforms that route everything through non-prescribing care teams create delays that can turn manageable side effects into emergency room visits.

The FormBlends clinical pattern: why some patients switch platforms mid-treatment

Across the patient population that switches to FormBlends from another telehealth platform mid-treatment, three patterns emerge consistently:

Pattern 1: The dose-escalation stall. Patients start on another platform, tolerate the initial doses well, then hit a wall at the first or second escalation. Nausea becomes severe, or reflux disrupts sleep, or constipation becomes unmanageable. They message the care team and get generic advice: "Drink more water, eat smaller meals, try ginger tea." The advice is correct but insufficient. What they need is a provider decision: stay at the current dose for another 4 weeks, or add an anti-nausea medication, or split the weekly dose into two smaller injections. The care team can't make that call, and the next provider consultation is 6 weeks away. The patient stops treatment or switches platforms to get faster provider access.

Pattern 2: The "we don't do that" response. A patient has a legitimate clinical need that falls outside the platform's standard protocol. They want to switch from semaglutide to tirzepatide because of intolerable side effects. They need lab work to rule out thyroid dysfunction before continuing. They want to add vitamin B12 to the compounded formulation because they're developing deficiency symptoms. The platform's response is "we don't offer that" or "you'll need to see your primary care doctor." The patient came to the platform specifically to avoid the hassle of coordinating multiple providers. They switch to a platform with more flexible clinical options.

Pattern 3: The transparency gap. The patient starts treatment, loses weight successfully, then starts asking questions. Where is the compounding pharmacy located? What API supplier do they use? What stability testing has been done on this specific formulation? Can I see a certificate of analysis? The platform provides vague answers or no answers. The patient loses confidence and switches to a platform that publishes pharmacy partnerships and sourcing information.

These patterns don't mean the original platform is bad. They mean the patient's needs evolved beyond what that platform's model can accommodate. The platforms optimized for scale and low cost tend to have rigid protocols and limited provider access. The platforms optimized for clinical flexibility tend to cost more and have slower onboarding.

When TryLife (or any compounded GLP-1 platform) is the right choice

Compounded GLP-1 platforms make sense for specific patient profiles:

You don't have insurance coverage for weight-loss medications. If your insurance doesn't cover Wegovy or Zepbound, or if the prior authorization process has failed multiple times, paying $300 to $400 per month for compounded medication is more sustainable than paying $1,000+ for brand-name.

You have obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities and have tried other weight-loss methods. GLP-1 medications are not first-line treatment for someone who hasn't attempted diet and exercise. They're for patients who have tried and not achieved sufficient weight loss. If you're in that category and cost is the barrier, compounded options are reasonable.

You're comfortable with self-injection and dose measurement. Compounded medications require you to draw doses with a syringe. If you're needle-phobic or have dexterity issues that make precise measurement difficult, brand-name pens are easier.

You want faster access than the insurance prior-authorization process allows. Prior authorization for weight-loss medications can take 4 to 8 weeks and often gets denied on the first attempt. Telehealth platforms can get you started in 3 to 7 days.

You're willing to accept the trade-off between cost and manufacturing oversight. Compounded medications are less expensive because they skip the FDA approval process and large-scale manufacturing quality controls. If you understand that trade-off and accept it, compounded options are appropriate.

When brand-name medications are worth the price premium

Brand-name medications (Wegovy, Zepbound, Ozempic, Mounjaro) are the better choice in these situations:

Your insurance covers them with reasonable copay. If your copay is $25 to $100 per month, brand-name is the obvious choice. You get FDA-approved manufacturing, pre-filled pens, and better dosing precision for less money than compounded alternatives.

You have a complex medical history or multiple medications. Patients with multiple comorbidities, organ dysfunction, or complex medication regimens benefit from the additional safety data that comes with FDA-approved drugs. The clinical trials for Wegovy and Zepbound included extensive subgroup analyses for patients with diabetes, cardiovascular disease, kidney disease, and other conditions.

You want the easiest administration method. Pre-filled pens require no dose measurement. You dial the dose, inject, dispose. Compounded vials require drawing the correct volume every time, which introduces user error.

You're risk-averse about medication sourcing. If the idea of using a non-FDA-approved medication makes you uncomfortable, that discomfort is a valid reason to pursue brand-name options even if they cost more.

You're participating in a clinical trial or research study. Most studies require brand-name medications with verified potency and lot numbers.

The decision framework: choosing between telehealth platforms

If you've decided compounded GLP-1 treatment is appropriate, how do you choose between TryLife, FormBlends, and the dozen other platforms?

Step 1: Check provider licensing in your state. Not all platforms operate in all states. Verify that the platform is licensed to provide telehealth services in your state and that the partner pharmacy can ship controlled substances to your address.

Step 2: Evaluate provider access.

• Can you message a provider directly, or only a care team?
• How quickly do they respond to clinical questions?
• Are follow-up consultations video-based or asynchronous?
• Do you see the same provider each time, or rotating staff?

Step 3: Ask about pharmacy sourcing.

• Which compounding pharmacy prepares the medication?
• Where is the pharmacy located?
• Who supplies the active pharmaceutical ingredient (API)?
• Is third-party testing done on finished product?
• Can you see a certificate of analysis?

Platforms that answer these questions transparently are more trustworthy than platforms that deflect or provide vague answers.

Step 4: Compare pricing across the full dose range. Some platforms advertise low starting prices ($199 per month) but charge significantly more at maintenance doses ($499 per month). Calculate the total cost over 6 to 12 months, not just the first month.

Step 5: Read the fine print on refunds and discontinuation.

• Can you pause treatment if you need a break?
• What's the refund policy if you have intolerable side effects?
• Are you locked into a subscription, or can you cancel anytime?
• What happens to unused medication if you discontinue?

Step 6: Assess educational resources. Does the platform provide detailed information about side effects, drug interactions, and what to do if something goes wrong? Or is the website mostly marketing copy with minimal clinical substance?

Platforms that invest in patient education tend to have better clinical outcomes because patients know what to expect and how to manage common issues.

Red flags that suggest a platform isn't clinically serious

Red flag 1: No provider consultation before prescription. Any platform that prescribes GLP-1 medications based solely on a questionnaire, without a synchronous or asynchronous provider review, is cutting corners. GLP-1 medications have contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis) that require provider evaluation.

Red flag 2: Promises of specific weight-loss amounts. "Lose 20 pounds in 8 weeks" or similar guarantees are not clinically appropriate. Weight loss on GLP-1 medications varies widely based on starting weight, adherence, diet, exercise, and individual response. Platforms that promise specific outcomes are prioritizing marketing over medicine.

Red flag 3: No mention of compounding or FDA approval status. If the website doesn't clearly state that the medication is compounded and not FDA-approved, the platform is being intentionally misleading. Transparency about what you're getting is the baseline standard.

Red flag 4: Extremely low pricing that seems too good to be true. If a platform is charging $149 per month for compounded tirzepatide when every other platform charges $299+, ask why. The API alone costs a certain amount. Compounding, shipping, and provider time add more. Prices significantly below market rate suggest either underdosing, questionable sourcing, or unsustainable business practices.

Red flag 5: No clear pathway for managing side effects. If the platform's FAQ says "contact your primary care doctor if you have side effects," they're not providing meaningful medical supervision. The platform prescribing the medication should have a protocol for managing common side effects.

Red flag 6: Aggressive upselling of unrelated supplements or services. Some platforms bundle GLP-1 prescriptions with expensive supplement packages, genetic testing, or other add-ons of questionable value. The medication works on its own. If a platform is pushing $200 per month of supplements as "essential" for results, they're prioritizing revenue over patient care.

FAQ

What is TryLife and how does it work for weight loss? TryLife is a telehealth platform that connects patients with licensed providers who can prescribe compounded semaglutide or tirzepatide for weight loss. After an online consultation, the medication is prepared by a partner compounding pharmacy and shipped to your home with syringes and supplies.

How much does TryLife weight loss cost per month? TryLife pricing typically ranges from $249 to $499 per month depending on medication type (semaglutide vs tirzepatide) and dose level. Starting doses are usually $249 to $299, while maintenance doses are $349 to $499. This includes provider consultations, medication, and shipping.

Is TryLife's medication the same as Ozempic or Wegovy? No. TryLife uses compounded semaglutide, which contains the same active ingredient as Ozempic and Wegovy but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. Compounded versions are not FDA-approved and have not undergone the same quality control and clinical validation as brand-name products.

Does insurance cover TryLife or other compounded GLP-1 medications? Usually not. Most insurance plans do not cover compounded medications because they are not FDA-approved. Patients typically pay out of pocket. Some platforms provide documentation for Health Savings Account (HSA) or Flexible Spending Account (FSA) reimbursement.

How much weight can you lose with TryLife's program? Published clinical trials of semaglutide show 15% average total body weight loss over 68 weeks, and tirzepatide shows 21% average loss over 72 weeks. Real-world results are typically lower (10% to 12% at 12 months) due to adherence challenges and less intensive lifestyle support than in clinical trials.

What are the side effects of compounded semaglutide and tirzepatide? The most common side effects are gastrointestinal: nausea (30% to 44% of patients), diarrhea (20% to 30%), constipation (20% to 24%), vomiting (10% to 24%), and acid reflux (6% to 9%). Most side effects are mild to moderate and decrease after the first 8 to 12 weeks. Serious but rare risks include pancreatitis, gallbladder disease, and thyroid tumors.

How long does it take to see results from TryLife weight loss medication? Most patients notice reduced appetite within 3 to 7 days of the first injection. Measurable weight loss typically begins in week 2 to 4. Significant weight loss (10% or more of body weight) usually takes 16 to 24 weeks at therapeutic doses with consistent adherence to diet and exercise.

Can I switch from TryLife to another GLP-1 platform mid-treatment? Yes. If you're switching platforms but staying on the same medication and dose, the transition is straightforward. Provide your new provider with your current dose and titration history. If you're switching medication types (semaglutide to tirzepatide or vice versa), your provider will create a new titration plan.

Is TryLife safe for people with diabetes? Compounded semaglutide and tirzepatide can be used by people with type 2 diabetes, but close monitoring is required because these medications lower blood sugar. Patients taking insulin or sulfonylureas may need dose adjustments to avoid hypoglycemia. Always disclose diabetes medications during your consultation.

What happens if I miss a dose of my TryLife medication? If you miss a dose by less than 5 days, take it as soon as you remember and resume your regular weekly schedule. If you miss by more than 5 days, skip the missed dose and take the next dose on your regular day. Do not double up. Missing multiple doses may require restarting at a lower dose to avoid severe side effects.

How do I inject compounded semaglutide or tirzepatide from TryLife? Draw the prescribed dose from the vial using an insulin syringe. Clean the injection site (abdomen, thigh, or upper arm) with an alcohol swab. Pinch the skin, insert the needle at a 90-degree angle, inject slowly, and dispose of the syringe in a sharps container. Rotate injection sites each week to avoid tissue irritation.

Can I stop TryLife medication once I reach my goal weight? GLP-1 medications are not a short-term fix. Most patients regain weight after discontinuation. The STEP 1 trial extension showed that patients who stopped semaglutide regained two-thirds of lost weight within one year. Long-term or indefinite use is typically needed to maintain weight loss, though some patients transition to lower maintenance doses.

Does TryLife offer tirzepatide (the same ingredient as Mounjaro and Zepbound)? Most compounded GLP-1 platforms, including TryLife, offer both compounded semaglutide and compounded tirzepatide. Tirzepatide tends to produce greater weight loss but costs more and has slightly higher rates of gastrointestinal side effects. Your provider can help determine which is more appropriate.

What's the difference between TryLife and other telehealth weight-loss platforms? The core service model is similar across most platforms: online consultation, compounded medication, home delivery, app-based support. Differences show up in provider access quality, pharmacy transparency, pricing structure, and clinical flexibility. Compare provider response times, pharmacy sourcing information, and protocols for managing side effects.

Are there any foods I should avoid while using TryLife weight-loss medication? No foods are strictly prohibited, but high-fat meals, large portion sizes, and carbonated beverages tend to worsen nausea and reflux. Most patients find that smaller, more frequent meals with moderate protein and fiber work best. Alcohol can increase nausea and should be limited, especially during the first 8 to 12 weeks.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Davies M et al. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2017.
4. Ghusn W et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open. 2022.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
8. American Society of Health-System Pharmacists. Survey on Patient-Reported Medication Errors in Compounded Weight-Loss Treatments. 2024.
9. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
10. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
11. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1 - 7 trials. Diabetes & Metabolism. 2019.
12. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. TryLife, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.